Medtronic PLC $MDT Stock Position Cut by Brady Family Wealth LLC

Key Points

• Brady Family Wealth cut its Medtronic position by 89.8% in the third quarter, selling 22,025 shares and retaining 2,492 shares valued at about $215,000.
• Institutional ownership stands at 82.06%, while Medtronic’s latest reported quarter beat analyst estimates for earnings and revenue; revenue rose 13.7% year over year.
• Analysts have a “Moderate Buy” consensus and an average price target of $102.88, below the stock’s cited Friday opening price of $104.92. Executives also reported share sales under pre-arranged trading plans.

Brady Family Wealth LLC reduced its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 89.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,492 shares of the medical technology company's stock after selling 22,025 shares during the period. Brady Family Wealth LLC's holdings in Medtronic were worth $215,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Activest Wealth Management lifted its position in shares of Medtronic by 470.9% in the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 259 shares in the last quarter. IAG Wealth Partners LLC acquired a new stake in shares of Medtronic in the second quarter worth approximately $30,000. Team Financial Group LLC acquired a new stake in shares of Medtronic in the third quarter worth approximately $31,000. Pin Oak Investment Advisors Inc. acquired a new stake in shares of Medtronic in the second quarter worth approximately $32,000. Finally, Community Bank N.A. purchased a new stake in shares of Medtronic during the second quarter worth approximately $33,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic and Recor reported real-world evidence of gains from renal denervation, potentially strengthening evidence for the treatment and its commercial prospects. The article provides no specific results in the supplied summary. Medtronic, Recor deliver real-world evidence of renal denervation gains
• Positive Sentiment: Medtronic reached a fresh 52-week high, signaling strong recent share-price momentum, although the milestone itself does not establish a change in fundamentals. Medtronic Breaks to $105 for a New 52-Week High
• Positive Sentiment: A new educational initiative with the Michael J. Fox Foundation aims to help people with Parkinson’s and caregivers understand deep brain stimulation. Greater awareness could support consideration of Medtronic’s established treatment, though any sales impact is uncertain. Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson’s Understand Deep Brain Stimulation
• Neutral Sentiment: Medtronic will report fiscal second-quarter 2027 results on November 24. The announcement sets a date for a potential market catalyst but offers no new guidance or results. Medtronic to announce financial results for its second quarter of fiscal year 2027
• Negative Sentiment: A reported analyst consensus price target of $102.88 is below the roughly $105 level cited in recent coverage, which could suggest limited expected upside at that estimate. Medtronic PLC Stock Has Consensus Price Target of $102.88 According to Analysts

Insider Transactions at Medtronic

In related news, EVP Michael Marinaro sold 10,420 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the sale, the executive vice president owned 105,916 shares of the company's stock, valued at approximately $10,167,936. This represents a 8.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Geoffrey Martha sold 50,000 shares of the firm's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the sale, the chief executive officer owned 277,866 shares of the company's stock, valued at approximately $26,397,270. The trade was a 15.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,903 shares of company stock worth $5,889,203 in the last quarter. Company insiders own 0.27% of the company's stock.

Medtronic Price Performance

MDT stock opened at $104.92 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The business has a 50 day simple moving average of $92.47 and a 200-day simple moving average of $88.43. The firm has a market capitalization of $134.21 billion, a PE ratio of 25.84, a price-to-earnings-growth ratio of 2.46 and a beta of 0.56. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm had revenue of $9.76 billion during the quarter, compared to analysts' expectations of $9.55 billion. During the same quarter last year, the firm earned $1.26 earnings per share. The business's revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 2.7%. The ex-dividend date was Friday, September 25th. Medtronic's dividend payout ratio is presently 70.94%.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Bank of America increased their price objective on Medtronic from $95.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, September 2nd. Wells Fargo & Company lifted their target price on shares of Medtronic from $102.00 to $104.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 2nd. UBS Group reaffirmed a "cautious" rating on shares of Medtronic in a research note on Wednesday, October 14th. Mizuho set a $115.00 target price on shares of Medtronic in a report on Wednesday, September 2nd. Finally, Robert W. Baird increased their target price on shares of Medtronic from $91.00 to $100.00 and gave the company a "neutral" rating in a research report on Wednesday, September 2nd. Eighteen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $102.88.

About Medtronic

Medtronic plc NYSE: MDT is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company's offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.